Glecaprevir; Pibrentasvir Patent Expiration
Glecaprevir; Pibrentasvir is used for treating chronic hepatitis C virus (HCV) infections across different genotypes and age groups. It was first introduced by Abbvie Inc
Glecaprevir; Pibrentasvir Patents
Given below is the list of patents protecting Glecaprevir; Pibrentasvir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mavyret | US10028937 | Anti-viral compounds | Jun 10, 2030 | Abbvie |
| Mavyret |
US10028937 (Pediatric) | Anti-viral compounds | Dec 10, 2030 | Abbvie |
| Mavyret | US10039754 | Anti-viral compounds | Jun 10, 2030 | Abbvie |
| Mavyret |
US10039754 (Pediatric) | Anti-viral compounds | Dec 10, 2030 | Abbvie |
| Mavyret | US10286029 | Method for treating HCV | Mar 14, 2034 | Abbvie |
| Mavyret |
US10286029 (Pediatric) | Method for treating HCV | Sep 14, 2034 | Abbvie |
| Mavyret | US11246866 | Solid pharmaceutical compositions for treating HCV | Jun 24, 2036 | Abbvie |
| Mavyret |
US11246866 (Pediatric) | Solid pharmaceutical compositions for treating HCV | Dec 24, 2036 | Abbvie |
| Mavyret | US11484534 | Methods for treating HCV | Mar 14, 2034 | Abbvie |
| Mavyret |
US11484534 (Pediatric) | Methods for treating HCV | Sep 14, 2034 | Abbvie |
| Mavyret | US8648037 | Macrocyclic proline derived HCV serine protease inhibitors | Jan 19, 2032 | Abbvie |
| Mavyret |
US8648037 (Pediatric) | Macrocyclic proline derived HCV serine protease inhibitors | Jul 19, 2032 | Abbvie |
| Mavyret | US8937150 | Anti-viral compounds | May 18, 2032 | Abbvie |
| Mavyret |
US8937150 (Pediatric) | Anti-viral compounds | Nov 18, 2032 | Abbvie |
| Mavyret | US9321807 | Crystal forms | Jun 05, 2035 | Abbvie |
| Mavyret |
US9321807 (Pediatric) | Crystal forms | Dec 05, 2035 | Abbvie |
| Mavyret | US9586978 | Anti-viral compounds | Nov 06, 2030 | Abbvie |
| Mavyret |
US9586978 (Pediatric) | Anti-viral compounds | May 06, 2031 | Abbvie |
| Mavyret | USRE48923 | Crystal forms | May 08, 2035 | Abbvie |
| Mavyret |
USRE48923 (Pediatric) | Crystal forms | Nov 08, 2035 | Abbvie |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳